title: [Drugs for sexual medicine].
abstract: OBJECTIVE
  To describe drugs used in sexual medicine.
  
  
  METHODS
  Pubmed search for efficacy, mode of action and side effects for each molecule. Additional data were searched from the French regulatory agencies web sites (HAS and ANSM).
  
  
  RESULTS
  5PDIs and intracavernous injection of alprostadil are first- and second-line therapies of erectile dysfunction. Dapoxetine is the first specific and approved treatment of premature ejaculation. Androgene supplementation improves sexual desire among patient with hypogonadism as much as initial serum testosterone levels are low. Female sexual dysfunctions pharmacology is to date less developed, although candidate drugs reach phase III clinical studies.
  
  
  CONCLUSIONS
  Pharmacology is one but not the only therapeutic avenue in sexual medicine. Despite real breakthrough such as 5PDIs for erectile dysfunction, incomplete knowledge and understanding of physiology, pathophysiology and pharmacology of human sexual function reduces its development particularly for women.
authors.affiliation: Aix-Marseille université, 13284 Marseille, France; Urologie et transplantation rénale, hôpital de La Conception, AP-HM, 147, boulevard Baille, 13385 Marseille cedex 05, France. Electronic address: gilles.karsenty@ap-hm.fr.
authors.forename: G
authors.initials: G
authors.lastname: Karsenty
authors.forename: F
authors.initials: F
authors.lastname: Marcelli
authors.forename: Geoffroy
authors.initials: G
authors.lastname: Robin
authors.forename: R
authors.initials: R
authors.lastname: Geoffroy
authors.forename: E
authors.initials: E
authors.lastname: Huygues
authors.forename: J-M
authors.initials: JM
authors.lastname: Rigot
authors.forename: S
authors.initials: S
authors.lastname: Droupy
authors.forename: C
authors.initials: C
authors.lastname: Bastide
authors.forename: L
authors.initials: L
authors.lastname: Guy
authors.forename: F
authors.initials: F
authors.lastname: Bruyère
mesh_terms: D000527:Alprostadil / Q000627:therapeutic use; D000728:Androgens / Q000627:therapeutic use; D001596:Benzylamines / Q000627:therapeutic use; D007172:Erectile Dysfunction / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007006:Hypogonadism / Q000188:drug therapy*; D008297:Male; D009281:Naphthalenes / Q000627:therapeutic use; D058986:Phosphodiesterase 5 Inhibitors / Q000627:therapeutic use; D008517:Phytotherapy; D061686:Premature Ejaculation / Q000188:drug therapy*; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D013739:Testosterone / Q000097:blood / Q000627:therapeutic use; D064804:Urological Agents / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use; D015016:Yohimbine / Q000627:therapeutic use
chemical_list: D000527:Alprostadil; D000728:Androgens; D001596:Benzylamines; D009281:Naphthalenes; D058986:Phosphodiesterase 5 Inhibitors; D017367:Selective Serotonin Reuptake Inhibitors; D013739:Testosterone; D064804:Urological Agents; D014665:Vasodilator Agents; D015016:Yohimbine; C080598:dapoxetine
keywords: 5PDIs; Dysfonction érectile; Déficit androgénique; Erectile dysfunction; IPDE5; Premature ejaculation; Testosterone; Testosterone deficiency; Testostérone; Éjaculation prématurée